Document 0535 DOCN M9440535 TI Treatment of cryptosporidial diarrhea in an AIDS patient with paromomycin. DT 9404 AU Danziger LH; Kanyok TP; Novak RM; Department of Pharmacy Practice, Colleges of Pharmacy and; Medicine, University of Illinois at Chicago 60612. SO Ann Pharmacother. 1993 Dec;27(12):1460-2. Unique Identifier : AIDSLINE MED/94138128 AB OBJECTIVE: To report a case of diarrhea caused by Cryptosporidium in an AIDS patients which was successfully treated with paromomycin. CASE SUMMARY: An AIDS patient with a 12-month history of cryptosporidial diarrhea unresponsive to other treatment measures was treated with paromomycin 500 mg q6h for 14 days. Before initiating therapy, the patient was experiencing, on average, 20 bowel movements per day and had lost more than 25 kg. After therapy was initiated, the number of bowel movements dropped to 1-2 per day and the patient began to gain weight. The diarrhea recurred when therapy was discontinued. After retreatment for 14 days with paromomycin 500 mg q6h, the diarrhea stopped. The patient has not had a recurrence of Cryptosporidium diarrhea, stool cultures remain negative for Cryptosporidium oocysts, and the patient has regained most of the weight. DISCUSSION: Literature concerning the use of paromomycin for the treatment of cryptosporidiosis is discussed. A treatment algorithm for the management of cryptosporidiosis in AIDS patients is presented. CONCLUSIONS: We believe that we have presented a clear example of a case in which paromomycin was effective in treating and eradicating intestinal cryptosporidiosis in an AIDS patient. Paromomycin is the most effective agent available to date for the treatment of this devastating complication of AIDS. DE Adult Animal AIDS-Related Opportunistic Infections/*DRUG THERAPY Case Report Cryptosporidiosis/*DRUG THERAPY *Cryptosporidium parvum Diarrhea/*DRUG THERAPY Feces/PARASITOLOGY Human Male Paromomycin/ADMINISTRATION & DOSAGE/*THERAPEUTIC USE Recurrence JOURNAL ARTICLE REVIEW REVIEW, TUTORIAL SOURCE: National Library of Medicine. NOTICE: This material may be protected by Copyright Law (Title 17, U.S.Code).